Press Releases

Search Press Releases
  
Subscribe for Email Alerts
8/22/2019
8:00 AM ET
Press Release

Mustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA

8/22/2019

RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine

https://www.globenewswire.com/NewsRoom/AttachmentNg/e475658d-f527-44f1-973d-e50185...

 Continue Reading
8/13/2019
8:00 AM ET
Press Release

Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases

8/13/2019

NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...

 Continue Reading
8/12/2019
8:00 AM ET
Press Release

Mustang Bio to Present at 11th Annual Bioprocessing Summit

8/12/2019

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...

 Continue Reading
8/9/2019
4:05 PM ET
Earnings Release

Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

8/9/2019

NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...

 Continue Reading
8/5/2019
8:00 AM ET
Press Release

FDA Clears IND for Mustang Bio’s MB-102 (CD123 CAR T)

8/5/2019

NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...

 Continue Reading
Displaying 1 to 5 (of 68 releases)